Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system
AssigneesExponential Biotherapies, Inc., The United States of America as represented by the Department of Health and Human Services
InventorsCarl R. Merril, Richard M. Carlton, Sankar L. Adhya
Life of this patent
Estimating the term…
Abstract
The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.
Claims1
A method of obtaining a bacteriophage with delayed inactivation by an animal's host defense system against foreign bodies, comprising:
- (a) parenterally injecting a bacteriophage into an animal;
- (b) obtaining serial blood samples over time and measuring the bacteriophage present in each sample;
- (c) growing a portion of the bacteriophage present in a blood sample obtained when about 0.1% to 1% of the bacteriophage remain in said blood samples from said animal, to high titer in a corresponding host bacteria;
- and
- (d) repeating steps (a), (b) and (c) at least once, to yield a bacteriophage that has delayed inactivation by an animal's host defense system,
- wherein step (d) is repeated until a bacteriophage is obtained which has at least a 15% longer half-life than a corresponding wild-type phage.
Dependencies are inferred from the claim text.